



















































































282. Abraham WT, Fisher WG, Smith AL *et al.* Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002;**346**:1845–1853.
283. Auricchio A, Stellbrink C, Sack S *et al.*, Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of haemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. *J Am Coll Cardiol* 2002;**39**:2026–2033.
284. Auricchio A, Stellbrink C, Butter C *et al.* Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. *J Am Coll Cardiol* 2003;**42**:2109–2116.
285. Higgins S, Hummel J, Niazi I *et al.* Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. *J Am Coll Cardiol* 2003;**42**:1454–1459.
286. Young JB, Abraham WT, Smith AL *et al.* Combined cardiac resynchronization and implantable cardioverter defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. *JAMA* 2003;**289**:2685–2694.
287. Abraham WT, Young JB, Leon AR *et al.*, Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic heart failure. *Circulation* 2004;**110**:2864–2868.
288. Bristow MR, Saxon LA, Boehmer J *et al.*, Comparison of Medical Therapy, Pacing, Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004;**350**:2140–2150.
289. Cleland JGF, Daubert JC, Erdmann E *et al.* The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure (the CARDiac RESynchronization-Heart Failure [CARE-HF] Trial). *N Engl J Med* 2005;**352**:1539–1549.
290. Bradley D, Bradley E, Baughmann *et al.* Cardiac resynchronization and death from progressive heart failure. *JAMA* 2003;**289**:730–740.
291. Mc Alister EA, Ezekowitz JA, Wiebe N *et al.* Systematic review: cardiac resynchronization in patients with symptomatic heart failure. *Ann Intern Med* 2004;**141**:381–390.
292. Freemantle N, Tharmanathan P, Calvert MJ, Abraham WT, Ghosh J, Cleland JGF. Cardiac resynchronization for patients with heart failure and left ventricular systolic dysfunction: a systematic review and meta-analysis. *Eur J Heart Fail* 2006;**8**:433–440.
293. Linde C, Leclercq C, Rex S *et al.* Long-term benefits of biventricular pacing in congestive heart failure: results from the MUSTIC study. *J Am Coll Cardiol* 2002;**40**:111–118.
294. Cleland JGF, Daubert JC, Erdmann E *et al.* Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [The Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. *Eur Heart J* 2006;**27**:1928–1932.
295. Duncan A, Wait D, Gibson D *et al.* Left ventricular remodeling and hemodynamic effects of multisite pacing in patients with left systolic dysfunction and activation disturbances in sinus rhythm: sub-study of the MUSTIC trial. *Eur Heart J* 2003;**24**:430–441.
296. Stellbrink C, Breithardt O, Franke A. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. *J Am Coll Cardiol* 2001;**38**:1957–1965.
297. St John Sutton M, Plappert T, Abraham W *et al.* Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. *Circulation* 2003;**107**:1985–1990.
298. Feldman AM, de Lissovoy G, De Marco T *et al.* Cost effectiveness of cardiac resynchronization therapy in the comparison of medical therapy, pacing and defibrillation in Heart failure (COMPANION) trial. *J Am Coll Cardiol* 2005;**46**:2311–2321.
299. Calvert M, Freemantle N, Yao G *et al.* Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. *Eur Heart J* 2005;**26**:2681–2688.
300. Yao GL, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. *Eur Heart J* 2007;**28**:42–51.
301. Leclercq C, Hare J. Ventricular resynchronization. Current state of the art. *Circulation* 2004;**10**:296–299.
302. Bleeker G, Schalij, Molhoek S *et al.* Frequency of left ventricular dyssynchrony in patients with heart failure and a narrow QRS complex. *Am J Cardiol* 2005;**95**:140–142.
303. Ghio S, Constantin C, Klersy C *et al.* Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. *Eur Heart J* 2004;**25**:571–578.
304. Bader H, Garrigue S, Lafitte S *et al.* Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. *J Am Coll Cardiol* 2004;**43**:248–256.
305. Yu C-M, Chan Y-S, Zhang Q *et al.* Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. *J Am Coll Cardiol* 2006;**48**:2251–2257.
306. Achilli A, Sassara M, Ficili S *et al.* Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and narrow QRS. *J Am Coll Cardiol* 2003;**42**:2117–2124.
307. Gasparini M, Mantica M, Galimberti P *et al.* Beneficial effects of biventricular pacing in patients with a narrow QRS. *Pacing Clin Electrophysiol* 2003;**26**:169–174.
308. Bleeker GB, Holman ER, Steendijk P *et al.* Cardiac resynchronization therapy in patients with a narrow QRS complex. *J Am Coll Cardiol* 2006;**48**:2243–2250.
309. Daubert JC. Atrial fibrillation and heart failure: a mutually noxious association. *Europace* 2004;**5**:S1–S4.
310. Baldasseroni S, Opasich C, Gorini M *et al.* Left bundle branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. *Am Heart J* 2002;**143**:398–405.
311. Leclercq C, Walker S, Linde C *et al.* Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. *Eur Heart J* 2002;**23**:1780–1787.
312. Gasparini M, Auricchio A, Regoli F *et al.* Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. *J Am Coll Cardiol* 2006;**48**:734–743.
313. Leclercq C, Cazeau S, Lellouche D *et al.* Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF study. *Pacing Clin Electrophysiol* 2007;**30**(Suppl. 1):S23–S30.
314. Brignole F, Gammage M, Puggioni E *et al.* Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. *Eur Heart J* 2005;**7**:712–722.
315. Doshi RN, Daoud EG, Fellows C *et al.*, PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). *J Cardiovasc Electrophysiol* 2005;**16**:1160–1165.
316. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. *J Card Fail* 2001;**7**:176–182.
317. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concept and clinical implications. A consensus paper from an international forum on cardiac remodeling. *J Am Coll Cardiol* 2000;**35**:569–582.
318. Janousek J, Vojtovic P, Hucin B *et al.* Resynchronization pacing is a useful adjunct to the management of acute heart failure after surgery for congenital heart defects. *Am J Cardiol* 2001;**88**:145–152.
319. Zimmerman FJ, Starr JP, Koenig PR, Smith P, Hijazi ZM, Bacha EA. Acute hemodynamic benefit of multisite ventricular pacing after congenital heart surgery. *Ann Thorac Surg* 2003;**75**:1775–1780.
320. Pham PP, Balaji S, Shen I, Ungerleider R, Li X, Sahn DJ. Impact of conventional versus biventricular pacing on hemodynamics and tissue Doppler imaging indexes of resynchronization postoperatively in children with congenital heart disease. *J Am Coll Cardiol* 2005;**46**:2284–2289.
321. Dubin AM, Feinstein JA, Reddy VM, Hanley FL, Van Hare GF, Rosenthal DN. Electrical resynchronization: a novel therapy for the failing right ventricle. *Circulation* 2003;**107**:2287–2289.
322. Zipes DP, Camm AJ, Borggrefe M *et al.* ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Circulation* 2006;**114**:e385–e484.
323. Moss AJ, Hall WJ, Cannom DS *et al.* Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. *N Engl Med* 1996;**335**:1933–1940.
324. Buxton AE, Lee KL, Fisher JD *et al.*, for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. *N Engl J Med* 1999;**341**:1882–1890.

325. Moss AJ, Zareba W, Hall JW *et al.* Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;**346**:877–883.
326. Bardy GH, Lee KL, Mark DB *et al.* Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;**352**:225–237.
327. Kadish A, Dyer A, Daubert JP *et al.* Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med* 2004;**350**:2151–2158.
328. Strickberger SA, Hummel JD, Bartlett TG *et al.* Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with non-ischemic dilated cardiomyopathy and asymptomatic non-sustained ventricular tachycardia—AMIOVIRT. *J Am Coll Cardiol* 2003;**41**:1707–1712.
329. Bansch D, Antz M, Boczor S *et al.* Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). *Circulation* 2002;**105**:1453–1458.
330. Rivero-Ayerza M, Theuns D, Garcia-garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. *Eur Heart J* 2006;**27**:2682–2688.
331. Auricchio A, Metra M, Gasparini M *et al.*, for the Multicenter Longitudinal Observational Study (MILOS) Group. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. *Am J Cardiol* 2007;**99**:232–238.
332. Gasparini M, Bocchiardo M, Lunati M *et al.* Comparison of 1 year effects of left ventricular and biventricular pacing in heart failure patients with ventricular arrhythmias and left bundle-branch block: the BELIEVE (Bi vs left ventricular pacing: an international pilot evaluation on heart failure patients with ventricular arrhythmias) multi-center prospective randomized pilot study. *Am Heart J* 2006;**152**:e1–e7.
333. Touiza A, Etienne Y, Gilard M *et al.* Long-term left ventricular pacing: assessment and comparison with biventricular pacing in patients with severe congestive heart failure. *J Am Coll Cardiol* 2001;**38**:1966–1970.
334. Blanc JJ, Bertault-Valls V, Fatemi M *et al.* Midterm benefits of left univentricular pacing in patients with congestive heart failure. *Circulation* 2004;**109**:1741–1744.
335. Blanc JJ, Etienne Y, Gilard M *et al.* Evaluation of different ventricular pacing sites in patients with severe heart failure. Results of an acute hemodynamic study. *Circulation* 1997;**96**:3273–3277.
336. Blanc JJ, Etienne Y, Gilard M *et al.* Left ventricular stimulation in treatment of heart failure. *Presse Med* 2000;**29**:1788–1792.
337. Wilkoff BL, Cook JR, Epstein AE *et al.* Dual-chamber or ventricular backup pacing in patients with an implantable defibrillator: the dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. *JAMA* 2002;**288**:3115–3123.
338. Sweeney MO, Hellkamp AS, Ellenbogen KA *et al.* Adverse effect of ventricular pacing in heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation* 2003;**107**:2932–2937.
339. Ritter P, Padeletti L, Gillio-Meina L, Gaggini G. Determination of the optimal atrioventricular delay in DDD pacing. Comparison between echo and peak endocardial acceleration measurements. *Europace* 1999;**1**:126–130.
340. Verbeek XA, Vernooij K, Peschar M *et al.* Intraventricular resynchronization for optimal left ventricular function during pacing in experimental left bundle-branch block. *J Am Coll Cardiol* 2003;**42**:558–567.
341. Parreira L, Santos JF, Madeira J *et al.* Cardiac resynchronization therapy with sequential biventricular pacing: impact of echocardiography guided VV delay optimisation on acute results. *Rev Port Cardiol* 2005;**24**:1355–1365.
342. Bernstein AD, Irwin ME, Parsonnet V. Antibradycardia-pacemaker follow-up: effectiveness, needs, and resources. *Pacing Clin Electrophysiol* 1994;**17**:1714–1729.
343. Sutton R. Guidelines for pacemaker follow up. Report of a British Pacing and Electrophysiology Group (BPEG) policy conference on pacemaker follow up. *Heart* 1996;**76**:458–460.
344. Petch M. Driving and heart disease. *Eur Heart J* 1998;**19**:1165–1177.
345. Pinski SL, Trohman RG. Interferences in implantable cardiac devices, part I. *Pacing Clin Electrophysiol* 2002;**25**:1367–1381.
346. Niehaus M, Tebbenjohanns J. Electromagnetic interference in patients with implanted pacemakers or cardioverter-defibrillators. *Heart* 2001;**86**:246–248.
347. Hayes DL, Wang PJ, Reynolds DW *et al.* Interference with cardiac pacemakers by cellular telephones. *N Engl J Med* 1997;**336**:1473–1479.
348. Pinski SL, Trohman RG. Interferences in implantable cardiac devices, part II. *Pacing Clin Electrophysiol* 2002;**25**:1496–1509.
349. Prasad SK, Pennell DJ. Safety of cardiovascular magnetic resonance in patients with cardiovascular implants and devices. *Heart* 2004;**90**:1241–1244.
350. Hayes DL, Strathmore NF. Electromagnetic interference with implantable devices. In: Elenbogen KA, Kay GN, Wilkoff BL, eds. *Clinical Cardiac Pacing and Defibrillation*. 2nd edn. Philadelphia: W.B. Saunders Company; 2000. p939–952.
351. Atlee JL, Bernstein AD. Cardiac rhythm management devices (part II): perioperative management. *Anesthesiology* 2001;**95**:1492–1506.
352. Pfeiffer D, Tebbenjohanns J, Schumacher B, Jung W, Luderitz B. Pacemaker function during radiofrequency ablation. *Pacing Clin Electrophysiol* 1995;**18**:1037–1044.
353. Langberg J, Abber J, Thuroff JW, Griffin JC. The effects of extracorporeal shock wave lithotripsy on pacemaker function. *Pacing Clin Electrophysiol* 1987;**10**:1142–1146.
354. Achenbach S, Moshage W, Diem B, Biebler T, Schibgilla V, Bachmann K. Effects of magnetic resonance imaging on cardiac pacemaker and electrodes. *Am Heart J* 1997;**134**:467–473.
355. Gregoratos G, Abrams J, Epstein AE *et al.* American College of Cardiology/American Heart Association Task Force on Practice Guidelines American College of Cardiology/American Heart Association/North American Society for Pacing and Electrophysiology Committee: ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). *J Cardiovasc Electrophysiol* 2002;**13**:1183–1199.
356. Hayes DL, Naccarelli GV, Furman S *et al.* Report of the NASPE Policy Conference training requirements for permanent pacemaker selection, implantation, and follow-up. North American Society of Pacing and Electrophysiology. *Pacing Clin Electrophysiol* 1994;**17**:6–12.
357. Rouleau F, Merheb M, Geffroy S *et al.* Echocardiographic assessment of the interventricular delay of activation and correlation to the QRS width in dilated cardiomyopathy. *Pacing Clin Electrophysiol* 2001;**24**:1500–1506.
358. Pitzalis MV, Iacoviello M, Romito R *et al.* Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. *J Am Coll Cardiol* 2002;**40**:1615–1622.
359. Sogaard P, Egeblad H, Kim WY *et al.* Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. *J Am Coll Cardiol* 2002;**40**:723–730.
360. Breithardt OA, Stellbrink C, Kramer AP *et al.*, Study Group. Pacing Therapies for Congestive Heart Failure. Echocardiographic quantification of left ventricular asynchrony predicts an acute hemodynamic benefit of cardiac resynchronization therapy. *J Am Coll Cardiol* 2002;**40**:536–545.
361. Yu CM, Fung WH, Lin H *et al.* Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. *Am J Cardiol* 2003;**91**:684–688.
362. Breithardt OA, Stellbrink C, Herbots L *et al.* Cardiac resynchronization therapy can reverse abnormal myocardial strain distribution in patients with heart failure and left bundle branch block. *J Am Coll Cardiol* 2003;**42**:486–494.
363. Bax JJ, Bleeker GB, Marwick TH *et al.* Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. *J Am Coll Cardiol* 2004;**44**:1834–1840.
364. Penicka M, Bartunek J, De Bruyne B *et al.* Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. *Circulation* 2004;**109**:978–983.
365. Gorcsan J III, Kanzaki H, Bazaz R *et al.* Usefulness of echocardiographic tissue synchronization imaging to predict acute response to cardiac resynchronization therapy. *Am J Cardiol* 2004;**93**:1178–1181.
366. Yu CM, Fung JW, Zhang Q *et al.* Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. *Circulation* 2004;**110**:66–73.
367. Bordachar P, Lafitte S, Reuter S *et al.* Echocardiographic parameters of ventricular dyssynchrony validation in patients with heart failure using sequential biventricular pacing. *J Am Coll Cardiol* 2004;**44**:2157–2165.

368. Yu CM, Bleeker GB, Fung JW *et al.* Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. *Circulation* 2005;112:1580–1586.
369. Marcus GM, Rose E, Vioria EM *et al.* Septal to posterior wall motion delay fails to predict reverse remodeling or clinical improvement in patients undergoing cardiac resynchronization therapy. *J Am Coll Cardiol* 2005;46:2208–2214.
370. Opasich C, Pinna GD, Bobbio M *et al.* Peak exercise oxygen consumption in chronic heart failure: toward efficient use in the individual patient. *J Am Coll Cardiol* 1998;31:766–775.
371. Ingle L, Shelton RJ, Rigby AS, Nabb S, Clark AL, Cleland JG. The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. *Eur Heart J* 2005;26:1742–1751.
372. Rector TS, Kubo SH, Cohn JN. Patients' self assessment of their congestive heart failure content, reliability and validity of a new measure—The Minnesota Living with Heart Failure questionnaire. *Heart Fail* 1987;3:198–207.
373. Butter C, Auricchio A, Stellbrink C *et al.*, Pacing Therapy for Chronic Heart Failure II Study Group. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. *Circulation* 2001;104:3026–3029.
374. Bernstein AD, Irwin ME, Parsonnet V *et al.* Report of the NASPE policy conference on antibradycardia pacemaker follow-up: effectiveness, needs, and resources. *Pacing Clin Electrophysiol* 1994;17:1714–1729.
375. Levine PA, Belott PH, Bilitch M *et al.* Recommendations of the NASPE policy conference on pacemaker programmability and follow-up programs. *Pacing Clin Electrophysiol* 1983;6:1222–1223.
376. Levine PA. Proceedings of the Policy Conference of the North American Society of Pacing and Electrophysiology on programmability and pacemaker follow-up programs. *Clin Prog Pacing Electrophysiol* 1984;2:145–191.
377. Fraser J, Gillis A, Irwin M *et al.* Guidelines for pacemaker follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing. *Can J Cardiol* 2000;16:355–376.
378. Adamson PB, Smith AL, Abraham WL *et al.* Continuous autonomic assessment in patients with symptomatic heart failure. Prognostic value of heart failure variability measured by an implanted cardiac resynchronization device. *Circulation* 2004;110:2389–2394.
379. Fantoni C, Raffa S, Regoli F *et al.* Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. *J Am Coll Cardiol* 2005;46:1875–1882.
380. Yu CM, Wang L, Chau E *et al.* Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. *Circulation* 2005;112:841–848.
381. Kindermann M, Frohlig G, Doerr T *et al.* Optimizing the AV delay in DDD pacemaker patients with high degree AV block: mitral valve Doppler versus impedance. *Pacing Clin Electrophysiol* 1997;20:2453–2462.
382. Bradley K, Desai A, Coman J *et al.* Long term retention of cardiac resynchronization therapy. *J Am Coll Cardiol* 2004;44:72–77.
383. Gras D, Böcker D, Lunati M *et al.*, on behalf of The CARE-HF Study Steering Committee and Investigators. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. *Europace* 2007;9:516–522.
384. Chauvin M, Cazeau S, Frank R *et al.* Recommendations from the French Cardiology Society concerning the competence, performance and the environment required for the implantation and surveillance of pacemakers. *Arch Mal Coeur Vaiss* 2006;99:275–278.